Scientists have employed CRISPR base editing to repair a cystic fibrosis (CF) mutation in cell and organoid models that is unresponsive to existing drugs, according to a report in Genetic Engineering News. The approach targets a specific genetic defect that has proven difficult to treat with current modulator therapies, offering a potential new avenue for patients with this subtype.
The study used base editing, a precise gene-editing technique that converts one DNA base to another without making double-strand breaks, to correct the mutation in laboratory-grown cells and organoids. The repair was successful in models carrying the hard-to-treat mutation, though the report does not specify efficacy rates or the exact proportion of cells corrected.
This work remains at the preclinical stage, conducted in cell and organoid models rather than in living organisms. No timeline for human trials or regulatory pathway was provided. The findings suggest a therapeutic strategy for the subset of CF patients whose mutations do not respond to approved drugs, but further validation is needed.
The discovery could open a new treatment path for patients who currently have no effective options, but it is early-stage research. No stock movements or market opportunity figures were mentioned in the source article.
While promising, base editing faces challenges including off-target effects and delivery to affected tissues, particularly in the lungs. Experts caution that translating these findings into a safe, durable therapy for CF will require years of additional research and clinical testing.